December 15th, 2015

Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines

[Reuters] – Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter . . . → Read More: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines Similar Articles: Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise 3M Company (NYSE:MMM) – 3M Co profit rises 6 pct as sales grow

Biogen Idec Inc (NASDAQ:BIIB) [Reuters] – Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market. Biogen said underlying patient demand for the drug represented about $348 million of the U.S. sales, still ahead of analysts’ consensus expectations of about $335 million. Biogen … [visit site to read more]

Similar Articles:
  1. Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
  2. Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise
  3. 3M Company (NYSE:MMM) – 3M Co profit rises 6 pct as sales grow
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.